Alla Kachko
Overview
Explore the profile of Alla Kachko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Kachko A, Selvaraj P, Rotstein D, Stauft C, Rajasagi N, et al.
NPJ Vaccines
. 2025 Feb;
10(1):30.
PMID: 39948345
Vaccines against SARS-CoV-2 have targeted the spike protein and have been successful at preventing disease. However, with the emergence of variants, spike-specific vaccines become less effective. The nucleocapsid protein is...
2.
Kachko A, Selvaraj P, Liu S, Kim J, Rotstein D, Stauft C, et al.
Vaccine
. 2023 Dec;
42(3):608-619.
PMID: 38142216
In this study, we evaluated the immunogenicity and protective immunity of in vitro transcribed Venezuelan equine encephalitis virus (VEEV TC-83 strain) self-amplifying RNA (saRNA) encoding the SARS-CoV-2 spike (S) protein...
3.
Zubkova I, Zhao Y, Cui Q, Kachko A, Gimie Y, Chabot S, et al.
Vaccine
. 2022 Dec;
41(4):955-964.
PMID: 36586740
Introduction: A hepatitis B vaccination (HepB) series with an initial dose of hepatitis B immune globulin (HBIG) is the recommended prophylaxis for infants born to mothers with chronic hepatitis B...
4.
Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler S, et al.
Sci Transl Med
. 2018 Jul;
10(449).
PMID: 29997251
The major route of hepatitis C virus (HCV) transmission in the United States is injection drug use. We hypothesized that if an HCV vaccine were available, vaccination could affect HCV...
5.
Kachko A, Costafreda M, Zubkova I, Jacques J, Takeda K, Wells F, et al.
J Virol
. 2018 Jan;
92(6).
PMID: 29321304
Hepatitis C virus (HCV) is the leading cause of chronic hepatitis in humans. Several host molecules participate in HCV cell entry, but this process remains unclear. The complete unraveling of...
6.
Tan W, Zubkova I, Kachko A, Wells F, Adler H, Sutter G, et al.
PLoS One
. 2017 Jul;
12(7):e0181578.
PMID: 28732046
T-cell based vaccines have been considered as attractive candidates for prevention of hepatitis C virus (HCV) infections. In this study we compared the magnitude and phenotypic characteristics of CD8+ T-cells...
7.
Guo N, Duan H, Kachko A, Krause B, Major M, Krause P
EBioMedicine
. 2015 Oct;
2(8):859-67.
PMID: 26425692
Research In Context: We used a large number of randomly produced small proteins ("peptides") to identify peptides containing specific protein sequences that bind efficiently to an antibody that can prevent...
8.
Kachko A, Frey S, Sirota L, Ray R, Wells F, Zubkova I, et al.
Hepatology
. 2015 Aug;
62(6):1670-82.
PMID: 26251214
Unlabelled: Hepatitis C virus (HCV) neutralization occurring at the E2 region 412-426 (EP-I) could be enhanced when antibodies directed specifically to the E2 region 434-446 (EP-II) were removed from serum...
9.
Kachko A, Loesgen S, Shahzad-Ul-Hussan S, Tan W, Zubkova I, Takeda K, et al.
Mol Pharm
. 2013 Oct;
10(12):4590-4602.
PMID: 24152340
Plant or microbial lectins are known to exhibit potent antiviral activities against viruses with glycosylated surface proteins, yet the mechanism(s) by which these carbohydrate-binding proteins exert their antiviral activities is...
10.
Duan H, Kachko A, Zhong L, Struble E, Pandey S, Yan H, et al.
J Virol
. 2012 Sep;
86(23):12686-94.
PMID: 22973024
Antibodies to epitopes in the E2 protein of hepatitis C virus (HCV) reduce the viral infectivity in vivo and in vitro. However, the virus can persist in patients in the...